Restricted accessResearch articleFirst published online 1999-12
A Retrospective Study of Late Outcome in Patients with Peripheral Arterial Occlusive Disease: An Association Between Prosthetic Vascular Graft and Cancer Death?
The authors assessed the relationship between cause of death and treatment modality in patients with peripheral arterial occlusive disease. A total of 273 patients were treated with percutaneous transluminal angioplasty, surgical reconstruction, amputation, or medical therapy. We evaluated the outcome in various patient subgroups divided by treatments with a mean follow-up of 4.9 years. Most patients died because of cardio vascular or cerebrovascular events, and cancer was the second most frequent cause of death. Furthermore, there was a significant difference in cancer deaths between patients who received prosthetic vascular grafts and those with other types of treatment (9.3% vs. 2.8%, p < 0.01, odds ratio = 3.34). It is noteworthy that patients with peripheral arterial occlusive disease succumbed to cancer, especially the patients with prosthetic vascular grafts.
Get full access to this article
View all access options for this article.
References
1.
Creager MA, Dzau VJ: Vascular diseases of the extremities. In: Harrison's principles of internal medicine, ed. 13, ed. by Isselbacher KJ, Braunwald E, Wilson JD, et al. New York: McGraw-Hill, 1994, pp 1135-1137.
2.
Veith FJ, Gupta SK, Samson RH, et al: Progress in limb salvage by reconstructive arterial surgery combined with new or improved adjunctive procedures. Ann Surg194:386-401, 1981.
3.
Veith FJ, Gupta SK, Wengerter KR, et al: Changing arteriosclerotic disease patterns and management strategies in lower limb-threatening ischemia. Ann Surg212:402-414, 1990.
4.
Tillgren C.: Obliterative arterial disease of the lower limbs. Acta Medica Scand178:103-119, 1965.
5.
Källero KS: Mortality and morbidity in patients with intermittent claudication as defined by venous occlusion plethysmography: A ten-year follow-up study. J Chron Dis34:455-462, 1981.
6.
Neugebauer J. , Heyn G.: Survival rates after reconstructions in the aorto-iliac region. J Cardiovasc Surg23:229-230, 1982.
7.
Van den Akker PJ, van Schilfgaarde R., Brand R., et al: Long-term success of aortoiliac operation for arteriosclerotic obstructive disease. Surg Gynecol Obstet174:485-496, 1992.
8.
Cox DR: Regression model and life tables. J R Stat SocB34:187-220, 1972.
9.
Kannel WB, McGee DL: Update on some epidemiologic features of intermittent claudication: The Framingham study. J Am Geriatr Soc33:13-18, 1985.
10.
Crawford ES , Bomberger RA, Glaeser DH, et al: Aortoiliac occlusive disease: Factors influencing survival and function following reconstructive operation over a twenty-five-year period. Surgery90:1055-1067, 1981.
11.
Cron JP, Cron C., Blanchard D., et al: Long-term of patients receiving an aorto-bi-femoral prosthesis for atherosclerotic occlusion disease of the aortic bifurcation. Int Angiol13:300-307, 1994.
12.
Brand KG: Cancer associated with absestosis, schistosomiasis, foreign bodies, and scars . In: Cancer 1. A. Comprehensive Treatise, ed. by Becker FF.New York: Plenum Press, 1982, pp 661-692.
13.
Brand KG, Johnson KH, Buoen LC: Foreign body tumorigenesis. CRC Crit Rev Toxicol5:353-394, 1976.
14.
Schoen FJ: Biomaterial-associated infection, neoplasia, and calcification: Clinicopathologic features and pathophysiologic concepts. Trans Am Soc Artif Intern Organs33:8-18, 1987.
15.
Clowes AW, Kirkman TR, Reidy MA: Mechanisms of arterial graft healing: Rapid transmural capillary ingrowth provides a source of intimal endothelium and smooth muscle in porous PTFE prostheses. Am J Pathol123:220-230, 1986.
16.
Clowes AW, Kirkman TR, Clowes MM: Mechanisms of arterial graft failure II: Chronic endothelial and smooth muscle cell proliferation in healing polytetrafluoroethylene prostheses. J Vasc Surg3:877-884, 1986.
17.
Graham LM: Growth factor production following prosthetic graft implantation. J Vasc Surg13:742-744, 1991.
18.
Ross R., Bowen-Pope DF, Raines EW: Platelet-derived growth factor and its role in health and disease. Phil Trans R Soc LondB327:155-169, 1990.
19.
Kaufman BR, DeLuca DJ, Folsom DL, et al: Elevated platelet-derived growth factor production by aortic grafts implanted on a long-term basis in a canine model. J Vasc Surg15:806-816, 1992.
20.
Westermark B., Heldin C.-H: Platelet-derived growth factor. Structure, function and implications in normal and malignant cell growth. Acta Oncologica32:101-105, 1993.
21.
Kalman PG, Rotstein OD, Niven J., et al: Differential stimulation of macrophage procoagulant activity by vascular grafts. J Vasc Surg17:531-537, 1993.
22.
Urayama H., Kasashima F., Kawakami T., et al: An immunohistochemical analysis of implanted woven Dacron and expanded polytetrafluoroethylene grafts in humans. Artif Organs20:24-29, 1996.
23.
Gordon S.: The mononuclear phagocyte system and tissue homeostasis. In: Oxford Textbook of Medicine, ed. 3, ed. by Ledingham GG, Weatherall DJ, Warrell DA.New York: Oxford University Press, 1996, pp 84-95.
24.
Cerutti PA: Prooxidant states and tumor promotion. Science227:375-381, 1985.
25.
Oberley LW, Buettner GR: Role of superoxide dismutase in cancer: A review. Cancer Res39:1141-1149, 1979.
